Contains Nonbinding Recommendations

Draft Guidance on Reserpine

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Reserpine

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 0.25 mg
   Subjects: Males and non-pregnant, non-lactating females, general population

   Additional Comments: Due to the long elimination half-life of Reserpine Tablets, applicants may conduct a single-dose, crossover study provided an adequate washout period is used. If the crossover study is problematic, applicants may use a bioequivalence study with a parallel design. For either a crossover or parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Applicants may use Cmax and a suitably truncated AUC to characterize peak and total drug exposure, respectively. For drugs that demonstrate low intrasubject variability in distribution and clearance, applicants may use an AUC truncated at 72 hours (AUC_{0-72} hr) in place of AUC_{0-4} or AUC_{0-inf}.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 0.25 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional Comments: Same as above

Analyte to measure (in appropriate biological fluid): Reserpine in plasma

Bioequivalence based on (90% CI): Reserpine

Waiver request of in-vivo testing: 0.1 mg strength based on (i) acceptable bioequivalence studies on the 0.25 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.
Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).